



## Cover Story

## Small molecule inhibitors to manipulate adenovirus gene transfer



The ultimate success of gene therapy relies on suitable delivery systems. In a time when gene therapy is being implemented with promising results in the clinic, efforts to improve the safety and efficacy of the vectors are imperative. Due to the safety concerns associated with using viral vectors, many non-viral gene delivery systems have been developed with acceptable efficacy. The non-viral delivery systems, however, are still not able to match the capability of viral vectors. Advances in vector design and novel strategies to improve therapeutic outcomes are closely linked to our growing knowledge of virus biology. Adenoviruses (Ad) in particular are of great interest in the gene therapy setting. Naturally, the flurry of studies aimed at understanding their complex *in vivo* infectivity profile has resulted in some major developments in the field. Coagulation factor X (FX) has been at the center of several of these studies and has been found to be a key factor in determining Ad tropism, immune recognition and evasion [1–4].

In this issue, Duffy and co-workers present their work focusing on the development of a high throughput screening assay and its use to identify small molecules capable of interfering with Ad transduction [5]. Realizing the important role of FX, they hypothesized that finding an inhibitor of Ad gene transfer in the presence of the coagulation factor would be of significant value in the *in vivo* setting—in particular to reduce or limit the profound liver gene transfer observed when adenovirus vectors are injected into the bloodstream. To test this, a robust fluorescent cell-based screen of a diverse array of pharmacological compounds was designed and effectively implemented. The development of the screen itself may be a valuable research tool. It is flexible to manipulate the general virus infection processes which consist of a complex range of distinct biological steps. After multiple rounds of *in vitro* screening, several small molecules were successfully identified that blocked Ad-mediated transduction; both *via* the classical CAR-mediated and critical FX-mediated infection pathways. It was interesting to note that the three most promising small molecule “hits” blocking Ad transduction shared similar chemical characteristics. Such information led the team to develop a pharmacophore model and investigate the most important chemical features of the hits. The subsequent testing of related compound libraries identified more potent hits. The properties of the small molecules can be improved through this iteration process.

The mechanism of action of the compounds was found to block efficient intracellular virus transport, and the data indicated that the compounds act independently of FX. While more studies are required to provide further insight into the precise mode of action, the study clearly demonstrated that small molecules are capable of preventing Ad transduction. The presence of two hit compounds substantially reduced transgene expression after subjecting mice to a high dose of virus *via* intravenous injection. The work by Duffy et al. offers an important proof-of-concept study and a tool that underpins future endeavors utilizing small molecules to manipulate Ad biology in gene therapy applications. If Ad vectors, and any viral vectors, can be used with enhanced safety without unexpected side effects, it will certainly make gene therapy safer and more practical. We look forward to the days when gene therapy becomes a routine process for clinical applications.

## References

- [1] S.N. Waddington, J.H. McVey, D. Bhella, A.L. Parker, K. Barker, H. Atoda, R. Pink, S.M.K. Buckley, J.A. Greig, L. Denby, J. Custers, T. Morita, I.M.B. Francischetti, R.Q. Monteiro, D.H. Barouch, N. van Rooijen, C. Napoli, M.J.E. Havenga, S.A. Nicklin, A.H. Baker, Adenovirus serotype 5 hexon mediates liver gene transfer, *Cell* 132 (2008) 397–409.
- [2] K. Doronin, J.W. Flatt, N.C. Di Paolo, R. Khare, O. Kalyuzhniy, M. Acchione, J.P. Sumida, U. Ohto, T. Shimizu, S. Akashi-Takamura, K. Miyake, J.W. MacDonald, T.K. Bammler, R.P. Beyer, F.M. Farin, P.L. Stewart, D.M. Shayakhmetov, Coagulation factor X activates innate immunity to human species C adenovirus, *Science* 338 (2012) 795–798.
- [3] Z. Xu, Q. Qiu, J. Tian, J.S. Smith, G.M. Conenello, T. Morita, A.P. Byrnes, Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement, *Nat. Med.* 19 (2013) 452–457.
- [4] O. Kalyuzhniy, N.C. Di Paolo, M. Silvestry, S.E. Hofherr, M.A. Barry, P.L. Stewart, D.M. Shayakhmetov, Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes *in vivo*, *Proc. Natl. Acad. Sci.* 105 (2008) 5483–5488.
- [5] M.R. Duffy, A.L. Parker, E.R. Kalkman, K. White, D. Kovalsky, S.M. Kelly, A.H. Baker, Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach, *J. Control. Release* 170 (2013) 132–140.

Kinam Park  
Purdue University,  
Departments of Biomedical Engineering and Pharmaceutics,  
West Lafayette, IN, USA  
E-mail address: [kpark@purdue.edu](mailto:kpark@purdue.edu).

## CONTENTS

Cited in: BIOSIS/Biological Abstracts; CAB Abstracts; Chemical Abstracts Services; Current Contents (Life Sciences); EMBASE/Excerpta Medica; International Pharmaceutical Abstracts; PUBMED/MEDLINE/Index Medicus; Polymer Contents; Science Citation Index. Also covered in the abstract and citation database SciVerse Scopus®. Full text available in SciVerse ScienceDirect®

## Cover Story

Small molecule inhibitors to manipulate adenovirus gene transfer  
K. Park (West Lafayette, U.S.A.) 160

## Reviews

Therapeutic cell encapsulation: Ten steps towards clinical translation  
E. Santos, J.L. Pedraz, R.M. Hernández and G. Orive (Vitoria, Spain) 1

Oral delivery of anticancer drugs: Challenges and opportunities  
K. Thanki, R.P. Gangwal, A.T. Sangamwar and S. Jain (Punjab, India) 15

Bacterial-directed enzyme prodrug therapy  
P. Lehouritis, C. Springer and M. Tangney (Cork, Ireland; Surrey, UK) 120

Formation of artificial multicompartiment vesosome and dendrosome as prospected drug and gene delivery carriers  
C.M. Paleos, D. Tsiourvas, Z. Sideratou and A. Pantos (Aghia Paraskevi, Greece; Alimos, Greece) 141

## Research Papers

Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer–drug conjugates and gold nanorod induced hyperthermia  
N. Larson, A. Gormley, N. Frazier and H. Ghandehari (Salt Lake City, USA) 41

Fusidic acid and rifampicin co-loaded PLGA nanofibers for the prevention of orthopedic implant associated infections  
S.E. Gilchrist, D. Lange, K. Letchford, H. Bach, L. Fazli and H.M. Burt (Vancouver, Canada) 64

Cell surface clustering of heparan sulfate proteoglycans by amphipathic cell-penetrating peptides does not contribute to uptake  
W.P.R. Verdurmen, R. Wallbrecher, S. Schmidt, J. Eilander, P. Bovee-Geurts, S. Fanghanel, J. Bürck, P. Wadhvani, A.S. Ulrich and R. Brock (Nijmegen, The Netherlands; Karlsruhe, Germany) 83

New PLGA–P188–PLGA matrix enhances TGF- $\beta$ 3 release from pharmacologically active microcarriers and promotes chondrogenesis of mesenchymal stem cells  
M. Morille, T. Van-Thanh, X. Garric, J. Cayon, J. Coudane, D. Noël, M.-C. Venier-Julienne and C.N. Montero-Menei (Angers, Montpellier, France) 99

In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application  
M. Rodriguez-Aller, D. Guillaume, M. El Sanharawi, F. Behar-Cohen, J.-L. Veuthey and R. Gurny (Geneva, Switzerland; Paris, France) 153

## Gene Delivery

Topical delivery of anti-TNF $\alpha$  siRNA and capsaicin via novel lipid–polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo  
P.R. Desai, S. Marepally, A.R. Patel, C. Voshavar, A. Chaudhuri and M. Singh (Tallahassee, Detroit, USA; Hyderabad, India) 51

Cell-penetrating cationic siRNA and lipophilic derivatives efficient at nanomolar concentrations in the presence of serum and albumin  
P. Perche, M. Nothisen, J. Bagilet, J.-P. Behr, M. Kotera and J.-S. Remy (France) 92

Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach  
M.R. Duffy, A.L. Parker, E.R. Kalkman, K. White, D. Kovalsky, S.M. Kelly and A.H. Baker (Glasgow, Cardiff, UK; Kiev, Ukraine) 132

## Nanomedicine

Oral delivery of taurocholic acid linked heparin–docetaxel conjugates for cancer therapy  
Z. Khatun, M. Nurunnabi, G.R. Reeck, K.J. Cho and Y.-k. Lee (Chungju, Republic of Korea; Manhattan, USA; Republic of Korea) 74

VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/PS1 mouse model of Alzheimer's disease  
E. Herrán, R. Pérez-González, M. Igartua, J.L. Pedraz, E. Carro and R.M. Hernández (Vitoria, Madrid, Spain) 111

(Contents continued at inside back cover)




0168-3659(20130828)170:1;1-Q

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SciVerse ScienceDirect


05054

ELSEVIER



# journal of controlled release

OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY  
AND THE JAPANESE SOCIETY OF DRUG DELIVERY SYSTEM



## COVER STORY

Small molecule inhibitors to manipulate adenovirus gene transfer